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Identification of antigenic epitopes in type IV collagen by use of
synthetic peptides. Peptides representing potential antigenic regions of
the NC-i and 7-S domains of the human ai and a2, and bovine a3
chains of type IV collagen were synthesized either chemically or by the
recombinant DNA technique and tested by ELISA using antibodies
raised in rabbits against the whole type IV collagen or the NC-i
domain.' Sera from patients with Goodpasture syndrome (GP) or with
acute poststreptococcal glomerulonephritis (APSGN) were also tested.
The location of antigenic determinants was predicted from the primary
and secondary structure of the chains, that is, aromaticity, hydrophilic-
ity and presence of 13-turns. All synthetic peptides reacted with the
antiserum to type IV collagen (anti-Col IV). Whereas all peptides
arising from the NC-i domain reacted with anti-NC-i, intact 7-S or
peptides of the al or a2 chain of the 7-S domain did not react. However
intact 7-S reacted with anti-Col IV. Two synthetic peptides from the
NC-i domain of ai, (a.a. 71-90 and a.a. 176-190), one from the a2 (a.a.
70-83) and four from the a3 chain (a.a. 72-89, a.a. 104-117, a.a. 133-145,
a.a. 185-203) reacted with anti-NC-i and anti-COL IV. The above
peptides, except a3 (72-89) and a3 (185-203), were tested and found to
be reactive with sera from patients with OP. Intact 7-S reacted with
several sera from patients with GP; however, only two synthetic
peptides from the 7-S domain of the a2 chain reacted with two of the GP
sera. One serum from a patient with GP reacted with intact 7-S but not
with NC-i. More than the presence of /3-turns and hydrophilicity, the
single most consistent predictor of immunoreactivity of synthetic
peptides from the NC-i domain was the presence of aromatic amino
acids. Sera of patients with APSGN reacted exclusively with the 7-S
domain. This reactivity resided in the synthetic peptide a2(IV) 1-18
from the 7-S domain. The results show that this approach can be used
to define more precisely the nature of antigenic epitopes that may be
involved in the mediation of immunologic injury in renal disease.
Basement membranes, which underly epithelial and endothe-
hal surfaces, contain a variety of macromolecules including
type IV collagen, laminins, entactin and heparan sulfate pro-
teoglycan. Circulating antibodies against type IV collagen bind
uniformly to the glomerular and alveolar basement membranes
in Goodpasture syndrome, an anti-glomerular basement mem-
'Abbreviations are: ELISA, enzyme-linked immunosorbent assay;
PBS, phosphate-buffered saline; PBS-T, PBS-Tween 20 buffer; ALC,
anterior lens capsule; GBM, glomerular basement membrane; NC-I,
non-collagenous domain at the carboxyl terminus of type IV collagen;
7-S. collagenous domain at the amino terminus of type IV collagen.
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brane disease (anti-GBM) [1]. Several studies have demon-
strated that the auto-antibodies are directed against an antigen
or antigens that have been located to the NC-i domain of type
IV collagen [2—4]. In another form of immunologically-mediated
renal disease, acute post-streptococcal glomerulonephritis
(APSGN), circulating antigen-antibody complexes deposit in
the glomerular capillaries. In both these forms of immune
response, once the antigen-antibody reaction has taken place,
common mediators of inflammation are activated leading to an
inflammatory response and, when severe, to destruction of
tissue [5]. Studies in our laboratory [6] have demonstrated that
sera from patients with APSGN react with type IV collagen and
laminin. In addition to antibodies against these antigens, Fillit et
al [7] demonstrated antibodies to glomerular heparan sulfate
proteoglycan in sera from patients with APSGN.
Our knowledge of the nature of antigenic epitopes in type IV
collagen which may potentially give rise to auto-antibodies is
limited. We decided, therefore, to use the method of Chou and
Fasman [81 to predict the secondary structure of the NC- 1
domains of al(IV) cs2(IV) and a3(IV) chains and determine the
hydropathy content according to the method of Kyte and Doolittle
[9] in order to select amino acid sequences that may be potentially
antigenic. The criteria that needed to be satisfied by the amino acid
sequences included the presence of one or more p-turns, hydro-
phiicity and aromaticity. A series of peptides were synthesized,
eight chemically and one by a recombinant DNA technique from
the NC-i domain, and three from the 7-S domain of type IV
collagen. The immunologic reactivity of these peptides with anti-
sera against intact type IV collagen (anti-Col IV), and the NC-i
domain and with sera from patients with Goodpasture syndrome
or APSGN was determined by ELISA.
The data demonstrate that peptides from several regions on
the NC-I domains react with the anti-Col IV and the anti-NC-i.
Sera from patients with Goodpasture's syndrome reacted pre-
dominantly with peptides from the NC-l domain, although two
synthetic peptides from the 7-S domain of the a2(IV) showed
reactivity by ELISA. The single most consistent predictor of
immunoreactivity of the synthetic peptides was the presence of
aromatic amino acids. Sera of patients with APSGN reacted
exclusively with the 7-S domain. The results demonstrate that
this approach can be used to define more precisely the nature of
antigenic epitopes that can give rise to auto-antibodies.
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Methods
Reagents
Human sera used in this study were obtained from patients
with glomerulonephritis or GP at a time when their antibody
titers against GBM were high and again when the titers were
low or absent as measured by the radioimmunoassay of Wilson
[10]. Each serum is designated by a number. Three sera from
patients with GP, designated PK, JC and JN, were obtained
from Dr. Ralph Butkowski of the University of Minnesota. Sera
from patients with APSGN were obtained from Trinidad [7].
Control sera were obtained from healthy adults and from
patients with rheumatoid arthritis, lung cancer and membra-
nous glomerulonephritis. Normal rabbit serum was obtained
from Cappel Laboratories (Malvern, Pennsylvania, USA).
Preparation of antigens
BM collagen (type IV). Native undegraded type IV collagen
was extracted from bovine ALC with 0.5 M acetic acid, and
purified on a DEAE-cellulose column as described by Brinker
et al [11].
Bacterial collagenase-resistant fractions of BM collagen. To
generate the NC-i and 7-S domains of type IV collagen, bovine
anterior lens capsules (ALC) were subjected to bacterial colla-
genase digestion [12]. Five hundred mg of lyophilized tissue
was suspended in 18 ml of 0.1 M Tris-0.4 M NaCI, pH 7.4 buffer
containing protease inhibitors (N-ethylmaleimide, 3 mi.i;
PMSF, 1 msi) and CaCl2 6 m. Bacterial collagenase (CLSPA-
Worthington Biochemicals, Freehold, New Jersey, USA) was
added at an enzyme/protein ratio of 1: 100, and the digestion
was allowed to proceed at 37°C for 20 hours. At the end of this
period, 1 ml of 100 mrvt EDTA was added, and the solubilized
protein was separated by centrifugation at 18,000 g for one hour
at 4°C. The supernatant was dialyzed exhaustively against
distilled water at 4°C and lyophilized. For gel filtration, 40mg of
the lyophilized digest was dissolved overnight at 4°C in a 2 ml
solution of 1 M CaCI2 containing 50 mri Tris, pH 8.5, and 40 ,sg
pepstatin (P-4265; Sigma Chemical Co., St. Louis, Missouri,
USA). The solution was warmed for 30 minutes at 45°C, and
then centrifuged at 18,000 g for 30 minutes at 22°C. The pellet
was discarded and the supernatant was placed on a 6% agarose
A-S m column (1.6 cm x 145 cm). Proteins were eluted with a
buffer containing I M CaC12, 50 mri Tris-HC1, pH 7.5, at room
temperature at a flow rate of 14.8 ml/hr. Essentially, the
material was resolved into seven fractions (Fig. 1) [12]. Fraction
III contained the 7-S domain and fractions IV, V and VI the
NC-i domain. We decided to work with fraction V since it
represented more than 90% of the NC-i content [12].
Rabbit antisera against type IV collagen and its NC-I
domain. The NC-I domain was prepared from bovine ALC by
digesting with bacterial collagenase as described above. Anti-
sera against the NC- 1 domain were prepared in rabbits by injecting
100 tg subcutaneously every other week for 11 weeks. The
immunogen was emulsified with an equal volume (1 ml) of
complete Freund's adjuvant. The rabbits were bled prior to
inoculation and bled out 1.5 weeks after the last injection [11].
Antisera against the intact type IV collagen were available in our
laboratory and were prepared as described by Brinker et al [11].
ELISA. Antibodies against type IV procollagen and its frac-
tions, in patients with anti GBM antibodies were detected by
ELISA. The assay was performed essentially according to
previously described methods of Engvall and Perlman [13],
using 96-well plastic plates. Native type IV procollagen was
coated in Vollers buffer (0.15 M Na7 CO3. 0.35 M NaHCO3,
0.02% NaN3) at a concentration of 600 ng/well. The noncollag-
enous NC-i domain of type IV collagen was coated at 1200
ng/well and the 7-S domain was coated at 300 nglwell. Synthetic
peptides were used at concentrations ranging from 300 ng to
1,200 nglwell.
Polyacrylamide gel electrophoresis (SDS-PAGE). SDS-
PAGE was performed on 5% or 9% polyacrylamide gels as
described by Laemmli [14].
Determination of secondary structure and hydropathy anal-
ysis. To determine the secondary structure of the NC-i domain
of the al(IV), a2(IV) and a3(IV) chains of type IV collagen we
used the method of Chou and Fasman [8]. The method of Kyte
and Doolittle [9] was employed to determine the distribution of
hydrophibic and hydrophilic amino acids within each chain.
Synthetic peptides. Twelve different peptides were synthe-
sized. Nine arose from the NC-I domain, representing residues
70-90, 176-190, 195-217 of the human al(IV) chain; 35-48, 70-83,
of the a2(IV) chain and 72-89, 104-117, 133-145 and 185-203 of
the bovine o3(IV) chain. Three peptides arose from the 7-S
A B
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Fig. 1. Comparison of secondary structure of the carboxyl-termina/ region (NC-I domain of the al (A), of the a2 chain (B) and of the cr3chain
(C) of type IV collagen. The prediction method of Chou and Fasman [8] was used. Hydrophilic regions are indicated by open circles. Hydrophobic
regions are indicated by concentric circles.
(A)
s1(IV) a.a. 70-90:
CNFASRNDYSYWLSTPEPMP
al(IV) a.a. 176-190:
CHGRGTCNYYANAYS
ai(IV) a.a. 195-217:
CTIERSEMFKPTPSTLKAGELRT
a2(IV) a.a. 35-48:
CFEGQEKAHNQDLGL
a2(IV) a.a. 70-83:
CYYASRNDKSYWLS
a3(IV) a.a. 72-89:
DVCNFASRNDYSYWLSTP
a3(IV) a.a. 104-117:
LEPYISRCTVCEGP
a3(IV) a.a. 133-145:
CPAGWISLWKGFS
a3(IV) a.a. 185-203:
CNYYSNSYSFWLASLDPKR
(B)
al(IV) a.a. 70-90:
CNFASRNDYSYWL STPEPMP
a2(IV) a.a. 70-83:
CYYASRNDKSYWLS
a3(IV) a.a. 72-89:
DVCNFASRNDYSYWLSTP
a2(IV) a.a. 35-48:
CFEGQEKAHNQDLGL
a3(IV) a.a. 104-117:
LEPYISRCTVCEGP
a3(IV) a.a. 133-145:
CPAGWISLWKG F S
aI(IV) a.a. 176-190:
CHGRGTCNYYAN AYS
al(IV) a.a. 195-217:
CT I ERS EM FK PT PSTLKAGELRT
a3(IV) a.a. 185-203:
CNYYSNSYSFWL A S LD P KR
5' C A
3'
TG TGT
ACA
CAC GGC CUT GGG ACC
GTG CCG GCA CCC TUG
TGC AAT TAC TAC
ACG TFA ATG ATG
GCA AAC GCT TAC AGC AGC T
CUT TFG CGA ATG TCG
Fig. 2. Synthetic oligonucleotide.
domain, representing residues 1-18, 136-148 and 197-202 of the
a2(IV) chain. Except for the peptide representing residues
176-190 of the al(IV) chain, which was synthesized by DNA
recombinant techniques (see below), the remaining eleven
peptides were synthesized chemically using an Applied Biosys-
tems 430A synthesizer by the solid-phase procedure of Barany
and Merrifield [15]. The synthesis was carried out on a 4-meth-
ylbenzhdrylamine resin with tert-butyloxycarbonyl-protected
amino acids, dicyclohexylcarbodilmide couplings, and trifluo-
roacetic acid (40%) for deprotection. The peptides were cleaved
from the resin with anhydrous hydrogen fluoride in the presence
of anisole as a scavenger. They were then washed with cold
ether and extracted with 10% acetic acid and lyophilized. Crude
peptides were purified by gel filtration on a Sephadex G-15
column equilibrated with 4% acetic acid followed by reverse-
phase high performance liquid chromatography on a C-18
column (Waters) using a 5 to 90% acetronitrile gradient con-
taining 0.1% trifluoroacetic acid. Purity and composition of the
peptides were confirmed by reverse-phase high performance
liquid chromatography as above, by capillary electrophoresis
using a Beckman P/ACE 2000 system and by amino acid
analysis using a Beckman Model 6300 analyzer.
Production of a peptide by recombinant DNA methods. For
the production of a peptide by recombinant DNA techniques we
selected the sequence in the NC-i domain of the ai(IV) chain
comprising residues 176-190 (Table 1). Selection of this peptide
sequence was based on the criteria listed earlier, namely,
presence of /3-turn, hydrophilicity and aromaticity (Fig. 1). In
addition, the coding sequence included features that aid in
subcloning, gene expression and protein purification. The syn-
thetic oligonucleotide we used to generate the amino acid
sequence contained in positions 176-190 of the ai(IV) chain of
the NC-i domain is illustrated in Figure 2.
We expressed the NC-i peptide as part of a fusion protein
utilizing a modification of the pAS expression vector system
described by Shatzman and Rosenberg [16]. In this system the
recombinant protein is fused to 81 amino acids of the influenza
virus NS-1 protein at a methionine residue to produce a stable
fusion protein. In this vector, transcription is under control of
the lambda P1 promoter and lyogenic bacterial harboring the
expression plasmid are induced with nalidixic acid during the
logarithmic growth phase.
Results
Production of synthetic peptides. The amino acid sequence of
the synthetic peptides arising from different regions of the NC-i
domain of al, a2 and a3 chains of type IV collagen appears in
Table 1. In column "A" the peptides are listed by alpha chain
and in column "B" by amino acid sequence clusters. The
selection of amino acid sequences was based on the predictabil-
ity of antigenicity from the secondary structure of each peptide
chain, that is, a-helix, /3-sheet, /3-turn and random coil, as well
as hydrophilicity profile and aromatic amino acid content (Fig.
1). For example, the peptide comprising residues 70-90 of the
ai(IV) chain is contained within two /3-turns, has a-helix, has
four aromatic amino acids and is hydrophilic (Fig. 1). The same
holds true for the recombinant peptide. However, though the
peptide comprising residues 195-217 of the al(IV) chain is
contained within a /3-turn, has a-helix and is very hydrophilic,
it contains only one aromatic amino acid. This peptide dis-
played the weakest reactivity with antibodies to the NC-i
domain and UP sera.
Similarly, peptides comprising residues 3 5-48 and 70-83 of the
a2(IV) chain were selected because they were contained within
/3-turns and were hydrophilic. But, whereas the former had only
one aromatic amino acid, the latter had four. In attempting to
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Table 1. Amino acid sequence of synthetic peptides from different regions of the NC-I domain of the alpha chains of Type IV collagen
arranged by alpha chains (A) and by sequence clusters (B)
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Table 2. Amino acid sequence of synthetic peptides from three non-
helical regions of the 7-S domain of the a2(IV) chain of type IV
collagen
a2(IV) a.a. 1-18
KFDVPCGGRD CS GGCQCY
a2(IV) a.a. 136-148
P YALGKEERDRYR
a2(IV) a.a. 197-202
GLGFYG
Table 3. Immunologic reactivity by ELISA of type IV collagen and
its domains (NC-I and 7-S)
Antigen
Absorbance 410 nm
Antiserum
Anti-Cot IV Anti-NC-i GP-Serum (Number)
Cot IV
(bOng)
NC-i
(600 ng)
7-S
(600 ng)
(1, 2, 4, 7, 23, 55)
>2 1.2 1.5— >2
1.8 >2 1.6 — >2
1.5 0.08 0.9, 1.3, 0.4, 0.5, 0.4
determine the reactivity of the above peptides with antisera to
type IV collagen and the NC-i domain we found out that the
content of aromatic acids was a better predictor. In selecting,
therefore, regions of the a3(IV) chain, we looked primarily for
those that contained more than one aromatic amino acid.
However, we again selected one region that had only one
aromatic amino acid, such as residues 104-i 17.
When we compared the various peptides of the NC-i domain
by sequence clustering (Table 1, B), we noted a high degree of
homology between ai(IV) 70-90, a2(IV) 70-83 and a3(IV) 72-89.
Each of the three peptides contained four aromatic amino acids.
Another cluster of two peptides, ai(IV) 176-190, and s3(IV)
185-203 has overlapping regions that are homologous and
contain three and five aromatic amino acids, respectively.
The peptides of the 7-S domain were selected from three
non-helical regions of the a2(IV) chain. Table 2 lists the three
peptides which comprise residues 1-18, 136-148 and 197-202.
We decided to synthesize the peptides from the a2(IV) rather
than the txi(IV) chain because the first two of the a2 chain
contain aromatic amino acids and are very hydrophilic.
Immunologic reactivity of type IV collagen and its NC-I and
7-S domains. Table 3 shows the reactivity by ELISA of type IV
collagen and the NC-i and 7-S domains with anti-Col IV,
anti-NC-i and GP sera. All three antigens reacted strongly with
the anti-Col IV. However, only Col IV and the NC-i domain
reacted with anti-NC-l. Similarly, Col IV and NC-i reacted
strongly with sera from six patients with GP. The 7-S domain
reacted strongly with one of the GP sera, moderately with
another and weakly with three more.
Immunoreactivity of the synthetic peptides. As shown in
Tables 4 and 5 all synthetic peptides from the NC-i and 7-S
domains reacted strongly by ELISA with the anti-Col IV,
except for two peptides, a2(IV) 35-48 and a3(IV) 133-145 whose
reaction was weak. The anti-NC-i serum reacted strongly with
all peptides except for ai(IV) 195-217 and cs2(IV) 35-48. Figure
3 shows an inhibition of the ELISA reaction of the anti-NC-i
domain serum with the NC-i domain. The competing antigens
were synthetic peptides, one from the isl and three from the a3
chain of the NC-i domain of type IV collagen. All peptides
tested, except the one comprising residues i04-i17 of c3(IV)
chain, inhibited the binding of NC-i domain to a variable
degree. Inhibition of binding ranged from 25% to 40%. The most
active peptides were those comprising residues 70-90 of al(IV),
i33-145 of a3(IV), 72-89 of 3(IV) and 185-203 of cs3(IV). None
of the synthetic peptides from the 7-S domain reacted with the
anti-NC-I (Table 5). As shown in Table 4, sera from four
patients with GP reacted with the csi(IV) 70-90 peptide, whereas
sera from two patients reacted strongly with the al(IV) 176-190
recombinant peptide. Control recombinant peptides of amylo-
genin (NS-i Amg), of elastin (NS-l El) and of the influenza
structural protein NS-i did not react with the anti-NC-i or three
of the GP sera. No or very low reactivity was noted with
peptide al(IV) i95-217 with any of the sera from five patients
with GP. Similarly, sera from seven patients with GP reacted
strongly with peptide a2(IV) 70-83 but showed no reactivity
with peptide a2(IV) 35-48. Two of the a3(IV) peptides tested,
comprising residues 104-117 and 133-145, showed moderate
reactivity with sera from three patients with GP.
Sera from five patients with GP gave very low or no reactivity
with the three synthetic peptides from the 7-S domain. One
peptide, a2(IV) i36-148, showed moderate reactivity (0.7 ab-
sorbance units) with one GP serum (patient #55).
Immunologic reactivity of type IV collagen and its fraction
with sera from patients with APSGN. Sera from patients with
APSGN were tested by ELISA with type IV collagen, the NC-i
domain, the 7-S domain and synthetic peptides comprising
residues a2(IV) 1-18, a2(IV) i36-i48 and cs2(IV) 197-202 of the
7-S domain and, al(IV) 70-90 of the NC-i domain.
Sera from five patients with APSGN were tested against the
intact type IV collagen and they all reacted strongly at an
antigen concentration of 600 ng/well and at serum dilutions
ranging from 1:10 to 1:50. Absorbance readings at 410 nm
ranged between 1.4 to 2.0 at 1: 10 dilution and between 0.6 to
i.0 at 1:50 dilution.
Sera from 18 patients with APSGN were tested against the
7-S domain. Eight of these sera were also tested against the
NC-i domain and against a synthetic peptide comprising resi-
dues al(IV) 70-90. As shown in Figure 4, fifteen of the eighteen
sera gave absorbance readings ranging between 0.55 and 1.9
when reacted with the 7-S domain. The sera from the first eight
patients tested gave very low absorbance readings with the
NC-i domain and the synthetic peptide al(IV) 70-90 from this
domain. The absorbance ranged between 0.2 and 0.25, which
was no higher than that obtained with four sera from control
patients. As shown in Figure 5, three synthetic peptides from
the a2 chain of the 7-S domain were also tested and only the
peptide comprising residues cs2(IV) 1-18 gave a strong reaction
by direct ELISA. This peptide was then tested by competitive
ELISA against the intact 7-S domain using the serum from one
of the patients with APSGN. As shown in Figure 6, the
synthetic peptide, a2(IV) i-18, inhibited the binding of the 7-S
domain to the extent of 30% at a concentration of 100 ng/mi.
Discussion
Humoral immune response can produce renal injury essen-
tially by two mechanisms. In the first, soluble antigens react
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Table 4. Immunologic reactivity by ELISA of type IV collagen NC-i domain and its synthetic peptides
Antigen
Absorbance 410 nma
Antiserum
OP-Serum (Number)
(11, 23, 55, W-I)
Anti-Col LV Anti-NC-I
NC-i (intact) 1.8 >2 1.2, 1,4, 1.5, 1.1
Synthetic peptides
al a,a. 70-90 1.2 1.4 1.0, 1.5, 1.6, 0.6
176-190 1.4 1.6 N.D., 1.1, 1.3, N.D.
(NS-1-NC-i) (55, W-1, PK, JC, JN)
195-217 1.5 0.6 0.3, 0.2, 0.2, 0.2, 0.2
(3, 8, 55, W-l, PK, JC, JN)2a.a. 35-48 0.5 0.2 0.l,0.1,0.3,0.1,0.l,0.l,Q.l
70-83 1.2 1.0 0.95, 1.0, 1.5, 0.9, 1.4, 0.8, 1.5
a3 a.a. 72-89 1.3 1.5 N.D.
104-117 1.2 1.25 N.D., 1.2, 0.5, 0.7, N.D., N.D., N.D.
133-145 0.5 0.9 N.D., 0.5, 0.6, 0.4, N.D., N.D., N.D.
185-203 1.5 1.6 N.D.
(11, 23, 55)
NS-l-Amg"
NS-l-EV'
N.D.
N.D.
0.05
0.01
N.D.
0.02, 0.05, 0.07
NS-i 81 a.a)' N.D. 0.02 0.01, 0.01, 0.05
a Average of four determinations
b NS-I influenza virus fusion protein expressed alone or with a recombinant peptide of amylogenin (Amg) or elastin (El). NS-l-NC-l is the fusion
peptide of residues al(IV) 176-190 of the NC-i domain.
Antigen
Absorbance 410 nm
Antiserum
GP-Serum (Number)Anti-Col IV Anti-NC-I
7-S (intact)
Synthetic peptides
a2 a.a. 1-18
136-148
197-202
1.5 0.08
1.2 0.08
1.8 0.05
1.6 0.04
(1,4, PK, JC, JN)
0.9, 1.3, 0.4, 0.4, 0.5
(55, W-1, PK, JC, JN)
0.35, 0.25, 0.15, 0.15, 0.15
0.7, 0.15, 0.15, 0.05, 0.02
0.5,0.4,0.1,0.l,0.1
with antibody to form antigen-antibody complexes [17]. Circu-
lating immune complexes can deposit in vascular sites including
the glomeruli and peritubular capillaries [17—191. Examples of
this would be post-streptococcal glomerulonephritis and sys-
temic lupus erythematosus. In the second, the reaction involves
circulating antibodies with antigens that are insoluble and fixed
within tissue. Antibasement membrane antibodies are a good
example and the condition which best exemplifies this type of
reaction is Goodpasture syndrome [20]. Although there is
compelling evidence that the principal antigenic epitope against
which circulating antibodies are produced in GP has been
localized to the NC- 1 domain of the a3 chain of type IV collagen
[21—23], it is not quite conclusive [24]. Most of the evidence
derives from in vitro studies using isolated peptide fractions
which do not take into consideration conformation dependent
reactions. Studies in our laboratory [6, 251 indicate that sera
from patients with GP react predominantly with the NC-i
domain and to some degree with the 7-S domain. There is
evidence that the serum of one patient with GP reacted only
with the 7-S domain [25].
In an attempt to understand better the nature of potentially
antigenic regions on the type IV collagen molecule we decided
Fig. 3. Inhibition of the ELJSA reaction of anti-NC-I domain serum
with NC-i domain of type IV collagen absorbed to microtiter wells,
using synthetic peptides as inhibitors. Symbols are: (El) NC-i domain;(•) human nl (70-90); () bovine a3 (72-89); () bovine a3 (104-117);(•) bovine a3 (133-145); (E) bovine a3 (185-203).
to approach the problem by the use of synthetic peptides. The
current study demonstrates that synthetic peptides can be used
to map antigenic epitopes on type IV collagen. The selection of
peptides from the NC-i domain was based on the ability to
predict the secondary structure [7] and hydropathy pattern [8]
from the amino acid sequences of the al, a2 and a3 chains of
type IV collagen (Fig. 1). The first three al(IV) and two a2(IV)
peptides to be synthesized fulfilled the criteria to a variable
degree, that is, n-turn content, hydrophilicity and aromatic
Table 5. Immunologic reactivity by ELISA of type IV collagen 7-S
domain and its synthetic peptides
CV
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amino acid content. When it became evident that the aromatic
amino acid content was the most critical factor in predicting
immunoreactivity, we selected four regions from the 3(IV)
chain that fulfilled the latter criterion. The selection of the three
peptides from the 7-S domain, essentially a collagenous do-
main, was based on their non-collagenous sequences. The
choice of the s2 chain over the al chain was based primarily on
the fact that the a2(IV) 1-18 and 136-148 sequences were in
addition more hydrophilic and had one and two tyrosines,
respectively. The reactivity of the intact type IV collagen, of
the NC-i domain and of the 7-S domain with anti-Col IV and
anti-NC-i was as expected high. However, the reactivity of the
7-S domain was, not surprisingly, nil with anti-NC-i. Both the
type IV collagen and the NC-i domain had strong reactions
with six sera from patients with GP. By comparison, the 7-S
domain had only a moderate reaction with two sera and a weak
reaction with three. Although, the significance of the reactivity
of the 7-S domain with GP sera is not presently clear, there is
evidence to suggest that there is heterogeneity in the nature of
antibodies in GP [25].
The reactivity of the synthetic peptides with anti-Col-IV,
anti-NC-i and the GP sera was high and predictable based on
the aromatic amino acid content. Peptides al(IV) 70-90, a2(IV)
70-83 and a3(IV) 72-89 are contained within a 13-turn and each
have four aromatic amino acids, but the first two are hydrophilic,
whereas the third is hydrophobic. Although peptide al(IV) 195-
217 reacted strongly with anti-Col IV, its reaction with anti-NC-i
was weak as was its reaction with sera from patients with GP sera.
Compared to the more reactive peptides, it has a 13-turn, is
hydrophilic but has only one aromatic amino acid. Similarly,
peptide a2(IV) 35-48, which was the least reactive, has a 13-turn, is
hydrophilic but contains only one aromatic amino acid.
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Fig. 4. Scattergram of the ELISA reaction of sera from 18 patients
with APSGN with the NC-i domain (•), the 7-S domain (El) of type IV
collagen and a synthetic peptide representing residues 70-90 of the
ai(IV) chain from the NC-i domain (D).
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Fig. 5. Direct ELISA reaction of a serum from a patient with APSGN
with synthetic peptides from the a2 chain of the 7-S domain of type IV
collagen. Peptides comprising residues 1-18 (El), 136-148 (•) and
197-202 (D) were used at concentrations ranging from 50 to 200 nglwell.
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Fig. 6. Inhibition of the ELJSA reaction of a serum from a patient with
APSGN with 7-S domain of type IV collagen absorbed to microtiter
wells, at 100 ng/well, using synthetic peptide a2(IV) 1-18 of the 7-S
domain.
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The recombinant peptide NS- 1-NC-i comprising residues
176-190 of the al(IV) chain was very reactive with anti-Col IV,
anti-NC-i and two GP sera. Like the other reactive peptides,
this one has three aromatic amino acids, has a /3-turn but it is
only moderately hydrophilic. Based on the immunologic reac-
tivity of the synthetic peptides, it can be stated that the
aromatic amino acid content had a higher predictive value of
antigenicity than either hydrophilicity or /3-turn presence.
In previous studies we demonstrated that sera from patients
with APSGN react with components of basement membrane,
including type IV collagen and laminin [121. Fillit et al [7] have
shown that sera from these patients react with glomerular
heparan sulfate proteoglycan. Our current study confirms the
reactivity of these sera with the 7-S domain and provides
evidence that the epitope responsible for this reaction resides in
the first 18 amino acids of the a2(IV) chain of the 7-S domain.
This is a significant difference in the reactivity of sera from
patients with APSGN compared to those from patients with GP
and may explain the reported difference in the distribution of
antibody on the GBM between the two diseases. Since the
earlier study [12] demonstrated that neither the NC-I, nor the
7-S domain reacted as strongly as intact type IV collagen with
the APSGN sera, it suggested that a major portion of the
antibodies in the APSGN sera must be directed against confor-
mational determinants. In the same study it was shown that the
carbohydrate content of 7-S is higher compared to the NC-i
domain. It should also be noted that 7-S contains 18 times more
mannose and —7 times more fucose than NC-i, suggesting that,
in addition to the glucosyl-galactose unit linked to hydroxy-
lysine, the 7-S domain contains mannose-rich oligosaccharide
units. The latter property may render the 7-S domain more
antigenic. Little or no reactivity was noted when pepsin-
resistant al(IV) collagen chains (Mr 125,000 and 110,000,
respectively) were tested against several APSGN sera (our
unpublished observation). The data presented here suggest that
the use of synthetic peptides is a useful tool for mapping
antigenic epitopes of basement membrane macromolecules that
may be involved in the mediation of immunologic renal disease.
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